Business
Neural Therapeutics and Hanf.com Sign Strategic Investment and Option Agreement to Create a Science-Backed Botanical Wellness Leader
Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, a leading German CBD retailer, are pleased to announce the signing of a strategic investment and option agreement dated May 28, 2025 (the "SIO Agreement") for Neural to
About this update from Neural Therapeutics Inc.
[{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, a leading German CBD retailer, are pleased to announce the signing of a strategic investment and option agreement dated May 28, 2025 (the "SIO Agreement") for Neural to acquire an interest in CWE through a series of transactions (the "CWE Transactions").","length":640,"tagName":"p"},{"type":"text","content":"Ian Campbell, CEO of Neural commented: "We are very pleased to finalize an agreement with Hanf.com. This is an important milestone in our strategy to build our asset base by making an investment into a revenue-generating and profitable health and wellness business. As we continue to advance our pharmaceutical and nutraceutical research and development programs, we expect that our partnership with Hanf.com will be a key aspect of long-term value creation."","length":469,"tagName":"p"},{"type":"text","content":"Ronnie Jaegermann, CEO of CWE, commented: "We are glad to have reached this milestone with Neural. The proposed investment is expected to provide CWE with much needed visibility in the public markets, especially during a time of rapid growth in the European CBD and cannabis markets. As we continue to execute our growth-through-franchising strategy we look forward to working with Neural as we achieve new heights."","length":426,"tagName":"p"},{"type":"text","content":"Strategic Rationale and Overview of Hanf.com ","length":44,"tagName":"p"},{"type":"text","content":"The proposed investment is expected to bring together Neural's R&D and intellectual property in psychedelics and botanicals with Hanf.com's high-traffic retail and digital distribution network across Germany- one of the largest cannabinoid markets in Europe. The transactions contemplated by the SIO Agreement, if completed, will mark a transformative milestone for Neural as it diversifies its business through a strategic investment into a revenue-generating business with a pulse in a key European wellness market, while maintaining its core focus on p...